New Hope in Lymphoma Treatment: Terbium-161 Radioimmunotherapy
Researchers at PSI have developed a targeted radioimmunotherapy using terbium-161 to effectively combat lymphoma, offering new hope for precise and effective treatment options.
Recent research conducted at the Paul Scherrer Institute (PSI) in collaboration with Bern University Hospital has highlighted promising developments in lymphoma treatment using radionuclide therapy. The study focuses on terbium-161, a radioactive isotope showing potential for targeted cancer cell destruction. The team attached terbium-161 to an antibody that specifically targets the CD30 receptor, a molecule found on the surface of many lymphoma cells. When injected into the bloodstream, this conjugate localizes to tumor sites and delivers lethal radiation directly to cancer cells, sparing healthy tissue.
Lymphoma affects nearly 2,000 individuals annually in Switzerland alone, with approximately 570 succumbing to the disease. Current treatments include radioimmunotherapy using lutetium-177, which is effective against larger tumors but less so for microscopic cancer cells or circulating tumor cells often seen in lymphoma. Terbium-161 offers a significant advantage due to its emission of not only beta particles but also conversion and Auger electrons, which have a range of less than one micrometer—roughly the size of a single tumor cell. This enables precise targeting and destruction of small tumor deposits or individual cancer cells, potentially reducing recurrence.
Laboratory tests and animal studies demonstrated terbium-161’s superior efficacy compared to lutetium-177, with treated mice surviving twice as long and some becoming tumor-free. The isotope’s half-life of 6.9 days facilitates transportation and clinical application without substantial activity loss, and its targeted nature minimizes side effects.
This innovative approach has already reached clinical trial stages for other cancers, and researchers believe terbium-161-based therapy could soon be adapted for lymphoma treatment. The team aims to optimize the drug further for human studies, with the hope of expanding treatment options for patients and improving long-term survival chances.
Source: https://medicalxpress.com/news/2025-06-terbium-powerful-treatment-lymphoma.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Maple-Derived Polyphenols Show Promise in Combating Tooth Decay
New research highlights how maple-derived polyphenols, especially epicatechin gallate, can inhibit bacteria responsible for cavities, opening doors for natural dental care solutions.
Measles Outbreak in Rural Canadian Town Highlights Vaccine Hesitancy and Community Divisions
An outbreak of measles in a rural Canadian town reveals deepening vaccine skepticism and community divisions, threatening public health gains. Learn more about this growing concern.
Poor Sleep May Accelerate Brain Aging and Increase Inflammation
Poor sleep quality is linked to accelerated brain aging and increased systemic inflammation, highlighting the importance of good sleep habits for cognitive health.
Revolutionizing Critical Care: Immune Cell Signatures as Guides for Treatment
Innovative blood tests analyzing immune cell gene signatures are set to revolutionize diagnosis and personalized treatment in critical care, enhancing outcomes for severely ill patients.